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ORIGINAL ARTICLE
Depletion of adult neurogenesis using the chemotherapy
drug temozolomide in mice induces behavioural and
biological changes relevant to depression
M Egeland1,2, C Guinaudie2, A Du Preez1,3, K Musaelyan1,2,3, PA Zunszain1, C Fernandes3, CM Pariante1 and S Thuret2
Numerous studies have examined links between postnatal neurogenesis and depression using a range of experimental methods to
deplete neurogenesis. The antimitotic drug temozolomide (TMZ) has previously been used successfully as an experimental tool in
animals to deplete adult neurogenesis and is used regularly on human patients as a standard chemotherapy for brain cancer. In this
study, we wanted to evaluate whether TMZ as a model for chemotherapy treatment could affect parameters related to depression
in an animal model. Prevalence rates of depression in patients is thought to be highly underdiagnosed, with some studies reporting
rates as high as 90%. Results from this study in mice, treated with a regimen of TMZ similar to humans, exhibited behavioural and
biochemical changes that have relevance to the development of depression. In particular, behavioural results demonstrated robust
deﬁcits in processing novelty and a signiﬁcant increase in the corticosterone response. Quantiﬁcation of neurogenesis using a novel
sectioning method, which clearly evaluates dorsal and ventral neurogenesis separately, showed a signiﬁcant correlation between
the level of ventral neurogenesis and the corticosterone response. Depression is a complex disorder with discoveries regarding its
neurobiology and how it relates to behaviour being only in their infancy. The ﬁndings presented in this study demonstrate that
chemotherapy-induced decreases in neurogenesis results in previously unreported behavioural and biochemical consequences.
These results, we argue, are indicative of a biological mechanism, which may contribute to the development of depression in
patients being treated with chemotherapy and is separate from the mental distress resulting from a cancer diagnosis.
Translational Psychiatry (2017) 7, e1101; doi:10.1038/tp.2017.68; published online 25 April 2017
INTRODUCTION
During the past decade, researchers in psychiatry, neuroscience,
as well as the pharmaceutical industry have placed intense
interest on the connections between depression, adult neurogen-
esis and antidepressants. A major hurdle, however, in elucidating
these connections is a lack of translational studies which conﬁrm
in humans, that which has already been done in in vitro and
animal studies. Recently, it has been established that the level of
hippocampal adult neurogenesis in humans is considerable
throughout life and may be even greater than that of rodents,
making the relevance of adult neurogenesis in human diseases an
even more pressing question.1,2 Obvious ethical implications of
experimentally decreasing adult neurogenesis in humans makes
human studies on the function of neurogenesis impossible.
However, the antimitotic mechanisms of many of the life-saving
chemotherapy treatments for cancer have the likely side effect
that they decrease adult neurogenesis.3 Studying the biological
and behavioural effects of chemotherapy in animal models may
be a way to begin a translational approach into understanding
how chemotherapy-induced decreases in adult neurogenesis may
affect humans and speciﬁcally, how it may affect the development
of depression.
A recent meta-analysis of the prevalence of depression in
cancer patients show that brain cancer is the subtype, which is
mostly associated with depression.4 Studies show that the
prevalence rates in this type of cancer are 28%. However,
depression in cancer patients is thought to be highly under-
diagnosed with one study pointing out that 93% of patients self-
reported symptoms of depression, whereas only 22% were
actually classiﬁed as depressed at some point during treatment.5
The devastating nature of cancer makes it difﬁcult to discern any
effects of psychosocial stress from potential side effects of the
treatment and was not examined in any of the mentioned studies.
However, harnessing the translational relevance using animal
models may help isolate any biological effects of these drugs
relevant to depression. Temozolomide (TMZ) is an antimitotic drug
that, due to its low levels of non-central nervous system toxicity
and increased survival rate, has become the standard form of
chemotherapy for brain cancers.6 TMZ has also recently been
developed as an experimental tool to decrease adult neurogenesis
in animals using a similar cyclic protocol used in the clinic, which
was found in rodents to reduce levels of adult neurogenesis by
80% at the end of treatment.7 Speciﬁcally, several studies have
used TMZ to examine different functions in animal models
thought to be neurogenesis dependent including aspects of
spatial learning and addiction.7–11 These studies have not,
however, addressed any potential links between neurogenesis
depletion as a result of TMZ with depression. Owing to its low
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toxicity in animals and published anti-neurogenic effects, TMZ is a
good drug to model the effects of chemotherapy.
The role that adult neurogenesis has in the development of
depression is continuing to be deﬁned.12,13 The results from
numerous studies in which neurogenesis is depleted using various
methods show the development of some depressive-like symp-
toms in some studies but not others,14,15 indicating that the idea
that a decrease in neurogenesis simply results in immediate
depression is unlikely. However, a consistent ﬁnding is that new
neurons are required for antidepressant efﬁcacy.16–18 The
neurobiological mechanisms resulting in the numerous symptoms
of depression are still largely undeﬁned as is the potential role of
adult neurogenesis in these mechanisms. A recent review in the
ﬁeld though suggests that the connection between neuropsy-
chiatric disorders and dysregulated hippocampal neurogenesis is
beyond correlation or epiphenomenon.12 An often-repeated
caution to the ﬁeld of depression research is the lack of suitable
methods with which to evaluate depression in experimental
models, indicating that results using established paradigms
should be interpreted carefully.
Deﬁnitions of anatomy may be one important factor that has
previously been underestimated in many studies and may
contribute to these conﬂicting results.19 It is becoming increas-
ingly evident that there are differences, including anatomical,
functional and molecular distinctions, along the dorsoventral
(septo-temporal) axis of the hippocampus.20 Furthermore, adult-
born neurons in the ventral dentate gyrus have previously been
shown to mature at a slower rate than those of the dorsal.21
In this study, we have combined knowledge about the
dynamics of adult neurogenesis with a new sectioning method
that allows greater dorsoventral segregation in addition to the
newly developed pharmacological method using TMZ to deplete
adult neurogenesis in mice. With these tools, we aimed to
investigate whether the high rates of depression seen in cancer
patients undergoing chemotherapy can partly be attributed to
biological changes as a result of a decrease in adult neurogenesis.
This study has particular relevance to cancer patients being
treated with TMZ but as all forms of chemotherapy have similar
cytostatic effects, there is a pertinent relevance of this study to all
forms of chemotherapy. By examining the behavioural and
biological changes of chemotherapy in animals, this study may
give some of the most translational idea to date of what can
potentially be occurring in humans with a chemotherapy-induced
depletion of adult neurogenesis.
MATERIALS AND METHODS
Animals
Eight-week-old male C57BL/6J mice were purchased from Charles River
Laboratories (Kent, UK). The mice were group housed (four per cage) in
standard cages measuring 32× 16× 14 cm. The housing rooms were kept
at an ambient temperature (21± 2 °C) and light (light/dark cycle with white
lights on from 0800 to 2000 h), with food (Rat and Mouse No. 1 Diet;
Special Diet Services, Essex, UK) and tap water available ad libitum. To
avoid the disruptive effect of cage cleaning on behaviour, Sawdust
(Litaspen premium), nesting materials (Sizzlenest; Datsand, Manchester,
UK) and a cardboard shelter (LBS Biotech, Horley, UK) were changed once
every 2 weeks, but never on the day before or the day of testing. All
housing and experimental procedures were performed in compliance with
the U.K. Home Ofﬁce Animals Scientiﬁc Procedures Act 1986. The work was
carried out under license (PPL: 70/7184) and all efforts were made to
minimize animal suffering and to reduce the number of animals used.
TMZ treatment
The mice belonging to the TMZ treatment group (n= 10) were injected
with TMZ (T2577, Sigma, Gillingham, UK) at a concentration of 25 mg kg− 1
(intraperitoneal injection, 2.5 mg ml− 1 in 0.9% NaCl) while controls (n= 10)
were injected with the 0.9% NaCl vehicle. To mimic the cyclic treatment
administered in the clinic, the animals were injected on 3 consecutive days
every week for a total of 6 weeks (Figure 1a). The mice were then allowed
to recover for a period of 6 weeks. Behavioural tests began after the
recovery period and ran over 3 weeks with the exception of the novelty-
suppressed feeding (NSF) test done before and after recovery.
Behaviour
The mice were 10 weeks old at the start of testing and the tests were
recorded using a camera positioned above the test arenas and the
Figure 1. TMZ treatment induces sustained decreases in adult neurogenesis. (a) The experimental design was performed as visually
represented. The mice were treated (25 mg kg− 1 temozolomide (TMZ)) in cycles of 3 days TMZ or vehicle (VEH) and 4 days recovery (n= 10).
(b) Signiﬁcant decreases in cell proliferation using ki-67 were found in both dorsal and ventral dentate gyrus (DG) of TMZ-treated mice
(*Po0.05, one-way analysis of variance (ANOVA)). Signiﬁcantly less cell proliferation (ki-67)/volume is found in the ventral vs dorsal DG
(#Po0.001, two-way ANOVA) (c) A signiﬁcant decrease in DCX-expressing immature neurons was present in ventral (*Po0.05, one-way
ANOVA) but not dorsal DG. Signiﬁcantly less differentiation (DCX)/volume is found in the ventral vs dorsal DG (#Po0.001, two-way ANOVA) (d)
Micrographs of hippocampus labelled with DCX presenting representive differences between the ventral and dorsal regions in staining
density. High magniﬁcation of representative DCX-positive cells demonstrating no differences in morphology of DCX+ cells between
treatment groups.
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movement of each mouse tracked using EthoVision software (Noldus
Information Technologies bv, Wageningen, The Netherlands; http://www.
noldus.com/site/doc200403002).
Novelty-supressed feeding
Novelty-suppressed feeding was measured according to previous
protocols.22 The testing setup consisted of a rectangular plastic box
(32 × 16 × 14 cm), the ﬂoor of which was covered with fresh bedding for
each mouse. The mice were food-deprived for 24 h before behavioural
testing. At the time of testing, a food pellet was placed on a square piece
of white cardboard (cage label) in the centre of the box. An animal was
placed in a corner of the box and the latency to eat the pellet was
measured. Food consumption over a 24 h period was then measured to
control for changes in appetite.
Sucrose preference
The mice were individually housed for 2 days with ad libitum access to
food and a choice of two bottle sippers, one containing tap water, the
other containing a 1% sucrose solution. The position of the bottles
alternated between day one and day two, to prevent side bias.
Consumption was measured 24 h and 48 h after the start of the test.
Sucrose preference was measured as sucrose solution consumption/total
ﬂuid consumption per day.
Open ﬁeld
The mice were placed facing the wall of a circular open-ﬁeld arena (40 cm
diameter) and allowed to freely explore the arena for 10 min according to
previous protocols.23 A small lamp placed on the test room ﬂoor provided
dispersed lighting (25 lux). In the EthoVision software, a central circle of
equal distance from the periphery, deﬁned as the ‘central zone’, was
virtually drawn within the arena. The frequency of entries into, and the
time spent in, the central zone of the arena were extracted in EthoVision, in
addition to the total distance travelled (cm).
Elevated plus maze
The mice were tested according to previous protocols.23 The maze
apparatus was made of acrylic and consisted of two opposing closed arms
(30 × 5 cm), which were enclosed by 15 cm high grey acrylic walls, and two
opposing open runways (30 × 5 cm), with 0.5 cm high grey acrylic ledges
around the open arms. The maze was elevated 40 cm from the ground on
a transparent acrylic stand. Light intensity in the open arms was 40 lux,
compared with 20 lux in the closed arms. The mice were placed on the
central platform, facing one of the open arms, and left to explore the maze
undisturbed for 5 min. The number of entries into, and the time spent in,
the open and closed arms were scored using EthoVision software. Zones to
measure entry/exit were deﬁned in EthoVision as an area where roughly all
four paws of the average mouse had entered an arm.
Forced swim test
The mice were placed for 6 min in a transparent cylinder measuring 15 cm
in diameter and ﬁlled with room temperature water to a depth of 40 cm, as
previously described.22 The activity in the trial was recorded using a
camera positioned perpendicular to the forced swim test and behaviours
were scored manually from the videotape using EthoVision; struggling
(deﬁned as a vertical posture with limb movement), swimming (deﬁned as
a horizontal posture with limb movement), paddling (deﬁned as horizontal
posture with minimal movement in one limb). Mean duration and latency
of immobility were extracted from the manual scores. (faecal boli were
removed at the end of each trial).
Tail suspension test
The mice were individually suspended by the tail from a horizontal bar
35 cm from the ﬂoor, using adhesive tape (distance from tip of tail was
2 cm). Trial duration was 6 min and each trial was videotaped and
subsequently scored for the number of seconds spent immobile.22
Immunohistochemistry
Directly after the last day of testing, the mice were prepared for ﬁxation by
ﬁrst being deeply anaesthetized with pentobarbitol (euthatal, 200 mg kg−1
body weight) and then perfused with cold phosphate-buffered saline
(PBS; 0.1 M; pH 7.4) followed by 4% paraformaldehyde. The brains were
removed, stored in ﬁxative overnight, transferred into 30% sucrose and
sectioned as described in the 'Results' section . The sections obtained using
this method were stored in PBS/sodium azide at 4 °C until staining was
performed. The primary and secondary antibodies were diluted in PBS saline
containing 0.1% Triton X-100 and 3% normal goat serum (NGS; Vector
Laboratories, Peterborough, UK, S-1000). Immunohistochemistry stainings to
visualize stages of adult neurogenesis were performed using 3,3-diamino-
benzidine. Brieﬂy, the sections were permeabilized (15 min. in 1% Triton
X-100/0.1 M PBS), blocked against endogenous peroxidases (20 min with 3%
H2O2/0.1 M PBS) and then incubated with NGS for 1 h followed by the
primary antibody. For primary antibody staining, the sections were
incubated overnight in either anti-Ki-67 (Abcam, Cambridge, UK, AB15580;
1:1000 in 10% NGS) or anti-DCX primary antibody (Abcam, AB18723; 1:1000
in 10% NGS). The sections were then incubated in anti-rabbit secondary
biotinylated antibody (Vector Laboratories, BA-9400; 1:250 in 3% NGS 2 h at
20 °C). A signal ampliﬁcation step was then performed by incubation in ABC
reagent (Vector Laboratories, PK-6100, Vectastain Elite ABC-Peroxidase Kits;
1:1000; for 1 h) followed by a reaction with 0.05% 3,3-diaminobenzidine
tetrahydrochloride/0.01% hydrogen peroxide (Sigma, D5637-5G) in PBS.
Finally, the sections were dehydrated and mounted on polylysine-coated
slides (Histolab), dried and coverslipped using DPX (Sigma, 44581).
Stereology
A stereological method was used to quantify the total number of
immunopositive cells using An Axioskop 2 MOT Zeiss microscope and a
semiautomatic stereology system (StereoInvestigator, Microbrightﬁeld,
Williston, VT, USA). With this system, the region of interest was manually
traced and the total number of immunopositive cells in the region of
interest counted. This was done for every sixth section throughout the
section of hippocampus (dorsal or ventral). Dorsal sectioning resulted in an
average of 8 sections per brain while the dorsal sectioning resulted in an
average of 6 (total 14 sections per brain). The software then estimated
the total number of positive cells per section of dentate gyrus. Because
Ki-67-positive cell are found in low numbers at this age, sampling with the
StereoInvestigator system was not possible with a reasonable coefﬁcient of
variance.24 Similar to previously published protocols,24,25 all individual Ki-
67-positive cells were manually counted using × 20 objective (Leitz, Leica
Microsystems, Milton Keynes, UK) on an Axioskop 2 MOT Zeiss microscope
in every sixth hippocampal section (dorsal or ventral) and this number
used to estimate the total number of Ki-67-positive cells per section of
dentate gyrus.
Corticosterone assay
Approximately 50 μl of whole blood was collected via tail sampling exactly
24 h before forced swim test (baseline or pre-stress measure) between
1000 and 1200 h and again 30 min after the forced swim trial (post-stress
measure). Forced swim testing was performed between 1000 and 1200 h.
Blood collection was completed within 120 s after removing each mouse
from its cage by a small incision using a scalpel at the base of the tail.
Blood obtained was collected into potassium-EDTA microvette CB 300
tubes (Sarstedt, Nümbrecht, Germany), stored on ice and centrifuged with
12 000 r.p.m. at 4 °C for 10 min to separate out the plasma. Blood plasma
was stored at –20 °C. Plasma corticosterone levels were determined in
duplicate from 20 μl of plasma using commercially available enzyme
immunoassay kits (Enzo Life Sciences, Lausen, Switzerland); sensitivity
30 pg ml− 1.
Statistical analysis
The mice with different treatments (TMZ or vehicle) were compared
primarily using two-tailed unpaired Student’s t-test when it was
appropriate. When additional variables were present, one-way analysis of
variance followed by Newman–Keuls post hoc test was used. Statistical
signiﬁcance was deﬁned as Po0.05. Statistical analyses of the data were
carried out with GraphPad Prism 6.
RESULTS
Novel sectioning method for greater segregation of the
dorsoventral dentate gyrus
The current gold standard for quantiﬁcation of adult neurogenesis
is via stereological quantiﬁcation of coronal sections. Owing to the
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‘J’-like shape of the mouse hippocampus (Figure 2a), it is not
possible when sectioning coronally to get numerous, similar and
thus representative sections of the ventral dentate gyrus.19 To
achieve a more accurate measure of potential differences in
ventral vs dorsal quantiﬁcations, a new sectioning method was
therefore devised and used in this study (see Figures 2a–d for the
description of method).
TMZ induces a sustained decrease in adult neurogenesis in the
ventral dentate gyrus
Previous studies7,8 have examined processes mainly associated
with the dorsal hippocampus and accordingly used a 4-week TMZ
treatment protocol to deplete an entire cohort of new neurons as
maturation of dorsal hippocampal neurons is roughly 4 weeks.
However, the maturation rate of the mood-associated ventral
dentate gyrus is slightly slower and is approximately 6 weeks.21 A
treatment paradigm was therefore devised here in which adult
male C57Bl6 mice were treated for a period of 6 weeks with
25 mg kg− 1 TMZ followed by a 6-week period in which the mice
recovered from any adverse effects of the drug (Figure 2a). Our
previous pilot studies demonstrated that at 6 weeks after
cessation of TMZ treatment, the mice have still a 60% decrease
in the levels of DCX+ immature newborn neurons (data not
shown).
The levels of neurogenesis were examined 9 weeks after
cessation of the TMZ treatment (Figure 1a). The comparison of the
results from quantiﬁcation of control mice alone demonstrated
that the volume controlled levels of both cell proliferation (Ki-67)
and differentiation (DCX) were signiﬁcantly less in the ventral vs
dorsal dentate gyrus (Figure 1b and c). The cell proliferation was
found to be 49% less in the ventral dentate gyrus whereas
differentiation was 51% less. Statistical analysis of this difference is
highly signiﬁcant for both markers using two-way analysis of
variance with region as a factor (Po0.001). This clearly indicates
that in brains from this study there are comparatively fewer
neurogenic total cells in the ventral dentate gyrus than in the
dorsal dentate gyrus.
Comparison of the effects of TMZ using Ki-67 showed
signiﬁcantly fewer positive number of total cells. A signiﬁcant
decrease was found both in the ventral (Po0.05) and dorsal
(Po0.05) dentate gyrus (Figure 1b). Thus, TMZ treatment resulted
in a sustained decrease in cell proliferation in both the dorsal
(30.8%, 392 average cells vehicle vs 300 TMZ) and ventral (35.4%,
219 average cells vehicle vs 159 TMZ) dentate gyrus 9 weeks after
cessation of TMZ treatment. Quantiﬁcation of DCX, an immature
neuronal marker, revealed a similar effect of TMZ with a signiﬁcant
decrease in the ventral dentate gyrus (Po0.05, 2136 average cells
vehicle vs 1410 TMZ) that was, however, insigniﬁcant in the dorsal
dentate gyrus (4241 average cells vehicle vs 3585 TMZ; Figure 1c).
Thus, a decrease in neurogenesis, measured using DCX, was also
sustained, albeit only in the ventral dentate gyrus (30.6%). In
summary, the TMZ treatment used in this study was sufﬁcient to
sustain decreased levels of neurogenesis, particularly in the
ventral dentate gyrus.
Acute stress induces a greater increase in corticosterone in mice
with TMZ
Stress and depression are integrally linked and, therefore, the
potential effects of TMZ-induced decreases in neurogenesis on the
biological stress response was examined. Accordingly, the acute
corticosterone response was measured in mice exposed to the
forced swim test. The blood samples were taken from the same
mouse 24 h before the stress exposure and 30 mins after. The
results from quantiﬁcation of corticosterone blood levels in
individual mice demonstrated no baseline difference between
the different groups (Figure 3a). However, in response to stress,
Figure 2. Novel sectioning method. (a) The J-shaped rodent hippocampus (green) makes it impossible to get uniform sections from both the
dorsal and dentate gyrus (DG) when sectioning in traditional coronal fashion. (b)To obtain sections for the ventral hippocampus, the brain was
frozen to the stand on it dorsal side and then sectioned at 40 μm along the axial plane from the ventral side of the brain toward dorsal
producing uniform ventral DG sections (inset, b). (c) When reaching the beginning of the third ventricle (left inset, c) marking the mid-section
of the DG, the specimen is detached, reoriented and attached by its caudal side in order to section the dorsal hippocampus along the coronal
plane (inset, d). For a one-in-six quantiﬁcation, this method gave approximately eight similar volume sections from both the dorsal and ventral
regions. These sections were then analysed using stereology.
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the TMZ-treated mice displayed a signiﬁcantly greater corticoster-
one response in comparison with untreated mice (Po0.05,
Figure 3b). This indicates that TMZ-induced decreases in neurogen-
esis increases the response to stress. This was further conﬁrmed by
examining the relationship between the individual level of ventral
neurogenesis (measured using DCX) and the corticosterone levels.
The results from this regression showed a signiﬁcant negative
correlation in that the mice with low levels of neurogenesis had a
higher corticosterone response (R2 = 0.2282, P=0.0216, Figure 3c).
This was speciﬁc to the ventral dentate gyrus as there was no
correlation between the dorsal levels of neurogenesis and the
corticosterone response (R2 = 0.0701, P=0.32, Figure 3d).
TMZ results in a transient reduction in sucrose preference
Anhedonia, a lack of pleasure seeking, is a core, diagnostic
symptom of depression and readily modelled using the sucrose
preference test. To assess the potential effects of TMZ-induced
decreases in adult neurogenesis on anhedonia, the mice were
presented with drinking bottles with a 1% sucrose/water solution
and plain water, respectively, for a period of 24 h. This was done
initially over a period of 2 days where the position of the bottles
was switched daily to avoid side preference confounds. The results
from the ﬁrst day of testing demonstrated a highly signiﬁcant
decrease in sucrose preference in the TMZ-treated mice (Po0.01,
Figure 4a). However, results from the second day show there was
no signiﬁcant difference in sucrose preference between groups
(Figure 4b). As this result could be an indication of side preference,
a third day of testing was performed. However, results from the
third day showed similar results to day 2 indicating no side
preference and no anhedonia. These results indicate a transient
decrease in sucrose preference when ﬁrst exposed to the sucrose
solution. Individual levels of sucrose preference on day 1 were
analysed in correlation with the respective levels of ventral
neurogenesis (measured using DCX). The results from this analysis
showed that, although not signiﬁcant, the transient decrease in
sucrose preference (day 1) was slightly correlated to a decrease in
neurogenesis (R2 = 0.1924, P= 0.078, Figure 4d). The mice with less
neurogenesis thus displayed a tendency toward less sucrose
preference. This was not the case with dorsal neurogenesis where
there was no correlation (R2 = 0.0018, P= 0.592, Figure 4e). The fact
that the sucrose preference is only transient indicates that the
TMZ-induced decrease in adult neurogenesis alone does not
robustly induce anhedonia.
TMZ results in robust effects in NSF
Examination of NSF—the phenomenon in which exposure to a
novel environment suppresses feeding behaviour—in conﬂict
with the increased drive to feeding following food restriction has
several aspects which make it relevant to the study of depression.
To examine the effect TMZ-induced reduction in neurogenesis
may have, two different cohorts of mice were exposed to the NSF
test at two different time points. The ﬁrst time point was
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Figure 3. Acute stress induces a greater increase in corticosterone in temozolomide (TMZ)-treated mice. (a) TMZ- and vehicle-treated mice
were exposed to an acute stress (forced swim) and blood samples were taken both at baseline (pre-stress) and after acute stress (post-stress).
(b) Baseline levels of corticosterone (pre-stress) showed no signiﬁcant differences between vehicle- and TMZ-treated mice (P40.05, n= 9);
whereas post stress, TMZ-treated mice show increased levels of corticosterone (Po0.05, n= 9). A signiﬁcant correlation (R2= 0.2282,
P= 0.0216) was found between the level of neurogenesis and the stress response in the dorsal (c) but not ventral (d) dentate gyrus (DG)
(R2= 0.0701, P= 0.32). *P⩽ 0.05.
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immediately after cessation of the TMZ treatment (time point 1,
Figure 4f) and the second was after a 6-week recovery period
(time point 2, Figure 4g). The results from the time point 1
revealed that TMZ treatment resulted in a highly signiﬁcant
latency to feed in comparison with untreated mice (Po0.001,
Figure 4f). At this time point, the majority of TMZ-treated mice did
in fact not make an attempt to feed within the 5 min test period.
No difference was found in food consumption for a 24 h period
after the NSF test, indicating no changes in appetite (Figure 4h).
However, other factors associated with the TMZ treatment may
have affected the NSF at this time point and therefore the effects
on hyponeophagia after the recovery period were also examined.
Although there was a larger degree of variation in comparison
with time point 1, results from time point 2 also revealed a
signiﬁcant increase in the latency to feed in the TMZ-treated mice
(Po0.05, Figure 4g). Both untreated and treated mice displayed
similar weights (data not shown) indicating again that the TMZ
treatment did not affect appetite. These results thus show that
TMZ treatment results in deﬁcits in hyponeophagia, which are
sustained for a substantial time period.
Anxiety-like behaviour is not robustly affected by TMZ
A decrease in the latency to feed in the NSF test is often
interpreted as an increase in anxiety. To further examine anxiety,
analysis of the behaviour of TMZ-treated mice in other paradigms,
which more speciﬁcally look at anxiety but do not have confounds
such as motivation present in the NSF, was performed. These
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paradigms included the open-ﬁeld test and elevated plus maze.
The analysis of the distance moved showed that there were no
signiﬁcant differences between TMZ-treated and untreated mice,
indicating that the treatment did not affect locomotion
(Figure 5a). Furthermore, analysis of the time spent in the centre,
a measure of anxiety, did not differ between groups indicating
that TMZ did not affect anxiety in the open-ﬁeld test (Figure 5b).
This lack of effect on anxiety was conﬁrmed using the elevated
plus maze. The results from analysis of behaviour in this test
showed no signiﬁcant differences in the time spent in the open
arms nor in the number of entries into the open arms (Figures 4c
and d). Therefore, results from the anxiety paradigms demonstrate
that TMZ alone does not result in an anxious phenotype.
Behavioural despair is not robustly affected by TMZ
Behavioural despair or the inability to attempt escape has been
suggested to indicate depressive-like behaviour. To investigate
the possibility that TMZ-induced decreases in adult neurogenesis
may cause an increase in behavioural despair, the mice from both
treatment groups were exposed to two behavioural despair
paradigms including the forced swim test and tail suspension test.
The analysis of data from the forced swim test show that mice
treated with TMZ had slightly increased level of immobility (18%)
that was though nonsigniﬁcant (Figure 5e). This indicates that
behavioural despair is not robustly induced by TMZ treatment.
Behavioural results from the tail suspension test conﬁrmed
this and show in fact a slight decrease in immobility (10%) that
was again nonsigniﬁcant (Figure 5f). Regression analysis of all
behavioural data showed no correlations with levels of
neurogenesis, thus further conﬁrming that TMZ-induced
decreases in neurogenesis do not appear to be sufﬁcient to
induce a depressive-like phenotype.
DISCUSSION
The results from the different behavioural paradigms show that in
mice, TMZ affects several different parameters, which may be
relevant to clinical depression. The most robust of these
behavioural ﬁndings is the effect of neurogenesis depletion on
hyponeophagia in the NSF test seen at different time points.
Classically the NSF test is often interpreted to be an indicator of
anxiety-like behaviour as well as anhedonia though this study as
well as previous studies report that despite clear results in the NSF,
neurogenesis depletion does not induce anxiety-like behaviour.26
In fact, a meta-analysis of studies examining anxiety-like effects
related to adult neurogenesis show that, in agreement with the
current study, decreases in neurogenesis have no effect on
anxiety.27 This indicates a deeper complexity of the NSF beyond
anxiety and indicates it likely is a measure of other behavioural
mechanisms. Indeed, the NSF test is one of the only tests that
responds to chronic antidepressant treatment and not acute
suggesting that this test engages biological processes, which have
parallels to depression and its treatment. Although the nature of
these biological processes remains to be conﬁrmed, several recent
ﬁndings suggest that a central function of adult neurogenesis and
even the mechanism central to the NSF test may be in the
processing of novel information.26,28 Whether memory processing
is important to the development of depression is currently
debatable as exempliﬁed in a recent paper in which changes in
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hyponeophagia were attributed to memory processing, rather than
being related to mood, making thus a clear distinction between
memory and mood.26 In contrast, recently it has been proposed
that neurogenesis may have a role in stress-related disorders
through its function in contextual emotional processing of
memories and that deﬁcits in neurogenesis may contribute to
depression via negative assessments of novel contexts thus altering
perception.29 Accordingly, the memory processing during the NSF
may therefore be directly related to mood, rather than being
distinct. Therefore, another interpretation is that the robust effects
seen in the NSF test indicate that reductions in neurogenesis
possibly affect contextual emotional memory processing.
Hyponeophagia is an assessment tool developed for animal
models but as described, the mechanistic tangents may be
relevant to human depression. Patients undergoing various forms
of chemotherapy, similar to TMZ, often present with depressive
symptoms suggested to be partly related to decreases in adult
neurogenesis.3 The emotional cost of cancer itself undoubtedly
has a role in the development of depression in patients. Adult
neurogenesis cannot be readily measured in living human
individuals but the fact that TMZ has such robust effects on
neurogenesis using a dosage and treatment cycle in mice that is
comparable to the treatment used clinically suggests that patients
treated with TMZ may also have depleted levels of adult
neurogenesis. It is therefore possible that chemotherapy-
induced reductions in neurogenesis also contribute to depression
via neurogenesis-dependent processes such as deﬁcits in con-
textual emotional processing of memories. The implications of this
are that patients being treated with chemotherapy may have
behavioural deﬁcits that have parallels to those seen in this study.
Another ﬁnding relating TMZ-induced changes to depression
are the effects on stress. In this study, mice that have been
exposed to an acute forced swim stress display an expected
increase in corticosterone. However, mice that have depleted
neurogenesis as a result of TMZ have an even greater
corticosterone response to stress, which is inversely correlated
to the individual levels of neurogenesis. A previous high-proﬁle
study by Snyder et al.30 has shown similar ﬁndings though this
was not correlated to individual levels of neurogenesis. One
possible reason this correlation has not been seen before may be
the method by which ventral vs dorsal has been sectioned for
quantiﬁcation, which may have led to dorsal regions being
quantiﬁed as ventral.31 The new method of sectioning described
here may allow the proper resolution necessary to observe this
correlation. Another factor that may affect both levels of
neurogenesis and stress levels are the home-cage environment
and light phases during which testing was done. Per local
regulations, home cages of all the groups in this study were given
shelter and nesting materials, which may be interpreted as slightly
enriched environment in comparison with other studies not
providing shelter or nesting material. Enrichment is known to
increase adult hippocampal neurogenesis32 and could not only
potentially mask even more prominent behavioural and neuro-
genesis changes in the TMZ groups, but may also similarly alter
stress responsivity in control groups. Alternatively, it could be
argued that the slightly enriched housing is more representative
of a natural environment and may result in more interpretable
ﬁndings. Regarding lighting, both this study and Snyder et al.30
were done during the light phase, whereas experiments done
during the dark phase have found the opposite effects that
neurogenesis impairs the stress response.33 Snyder et al.30
attribute the increase in stress-induced corticosterone response
seen in neurogenesis-depleted animals to an impairment of
negative feedback on the hypothalamic–pituitary–adrenal axis.
Although this mechanism may be a contributing factor to this
observed phenomenon, several challenges in direct response to
this idea were raised including a lack of GR receptors in young
neurons,34 and the potential for circuitry-related mechanisms,
which theoretically may also cause changes in stress regulation
proposed by Gould and colleagues.35 Along similar lines of this
suggested alternative mechanism,35 the changes in stress
perception in the theory described above regarding impaired
contextual emotional processing may also affect stress reactivity.29
For example, human measurements of cortisol levels in response
to stress show that individuals with deﬁcits in emotional
regulation have a higher cortisol reactivity.36 Although there are
obvious limitations in rating individual experiences of stress or
emotional regulation in animals, corticosterone may similarly be
related to emotional regulation and stress reactivity. Therefore,
neurogenesis-deﬁcient mice may have deﬁcits in contextual
emotional processing causing the observed increase in cortisol
to simply be the result of an increased perception of stress. The
TMZ-induced changes in corticosterone response again may have
important implications for patients treated with chemotherapy as
glucocorticoid levels in humans may be similarly affected. Indeed,
previous clinical studies indicate dysregulation of the glucocorti-
coid system in cancer patients treated with different chemother-
apy treatments.37–39 Although hormonal stress response reactivity
has not been measured in these studies, one study reported
changes in diurnal glucocorticoid rhythm in treated patients that
was furthermore associated with depression.39 Measurements of
the acute stress response in this study present only a limited
aspect of stress-response regulation as a result of neurogenesis
depletion. Clearly these results as well as reported clinical deﬁcits
in patients indicate that further investigation is warranted and
may be of clinical importance.
The results from the sucrose preference indicate that in this
study, anhedonia is affected but only transiently. Previous studies
examining the effects of depleted neurogenesis on anhedonia
show again contrasting results with neurogenesis depletion
resulting in both an increase in anhedonia and no effect.30,33 In
the present study, a lack of habituation period, which is however
present in the referenced studies, allowed the observance of the
transient decrease, which would otherwise have not been
observed. This transient period is interesting, nonetheless, as it
indicates a neurogenesis depletion-induced difference in beha-
viour is related to anhedonia. The connection between the
observed behaviour and neurogenesis is further supported by the
trend seen in the correlation between transient decreased sucrose
preference and ventral neurogenesis levels in this study. A similar
correlation in whole hippocampus has previously been reported in
rats.40 Alternatively, however, the reason for this effect may be
similar to the observation in the NSF test and is the response
of neurogenesis-depleted mice toward novelty, in this case,
the presentation of a new taste. Therefore, the transient decrease
in sucrose preference may possibly be a result of transient
anhedonia, a deﬁcit in novelty processing or a combination of both.
TMZ as an experimental depletion method is relatively
inexpensive and is easily injected, making this pharmacological
approach a much more available alternative to decrease adult
neurogenesis. Some genetic models of neurogenesis ablations are
absolute and permanent, whereas TMZ induces an 80–90%
reduction which then slowly recovers. An advantage of this is
that there is a general uniformity in the level of depletion across
groups, whereas other methods which require precise injections
will result in highly variable levels of depletion. In our study, the
recovery time allowed a substantial recovery of 6 weeks yet robust
behavioural effects were still present while neurogenesis deﬁcits
were still present after 9 weeks of recovery. This indicates that
total ablation is not necessary to observe biological and
behavioural changes and that in fact, such depletion levels are
likely more translational and more representative to the clinical
scenario. In addition, methods inducing a total ablation may
initiate compensation mechanisms, which may lead to misinter-
pretation of results. However, a speciﬁc disadvantage of TMZ
depletion is the global nature of the depletion. Some depletion
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methods allow a spatial speciﬁcity targeting only the hippocam-
pus, whereas TMZ also affects the other neurogenic niche as well
as other types of cell division. Although TMZ has less side effects
than other antimitotic compounds, it still has the potential to
affect other tissues. This was in a previous study, however, found
to be minimal and a non-issue after sufﬁcient recovery time.7
Previous studies have also demonstrated that TMZ affects certain
aspects of cognition, particularly spatial and associative
learning.7,11 Although these types of cognition are unlikely to
affect the parameters measured in this study, it cannot be
excluded that other types of potential cognitive deﬁcits due to a
decrease in adult neurogenesis may have an effect on a
depressive-like phenotype. Indeed, cognitive deﬁcits in them-
selves are considered to be an important aspect of depression.41
As TMZ is the standard treatment for cancers of the brain,
thousands of patients are treated with this drug. In addition to its
utility as an experimental tool in animal models, studying the
effects of TMZ has important translational implications for all
patients being treated with chemotherapy. Although it is not
possible to experimentally deplete adult neurogenesis in humans,
this study gives strong evidence that chemotherapy-induced
decreases in adult neurogenesis may affect the stress response
and behaviours related to processing novelty, both of which
ultimately may contribute to depressive symptoms. In addition to
TMZ, the antimitotic action of other cancer drugs has already been
demonstrated in animal models to decrease neurogenesis and
affect spatial memory,42 though these do not affect neurogenesis-
independent functions such as fear conditioning and novel object
recognition.43 Although no changes in depressive-like behaviour
have been noted in other studies, it is likely that other types of
chemotherapy may similarly affect behaviours and biological
parameters, which have the potential to contribute to depression.
Despite their potential side effects, TMZ and other forms of
chemotherapy are indispensable for increasing patient-survival
rates. However, future studies, which harness the beneﬁt of doubt
of these antimitotic drugs and examine their effects on
neurogenesis depletion may yield new insights into neurogenesis
function in humans, an area of study that is otherwise highly in
need for translational veriﬁcation. Studying the speciﬁc effects of
chemotherapy on mood may also initiate important changes in
prophylactic and post-chemotherapy treatments, which may
increase the quality of life for those affected.
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